共 50 条
- [41] First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAsJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S358 - S358Ou, S. -H. I.Kilvert, H.Candlish, J.Jaiyeola, C.Polli, A.Thomaidou, D.Le, H.Lee, B.
- [42] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Plimack, Elizabeth R.Rini, Brian, IStus, ViktorGafanov, RustemWaddell, TomNosov, DmitryPouliot, FredericSoulieres, DenisMelichar, BohuslavVynnychenko, IhorAzevedo, Sergio JobimBorchiellini, DelphineMcDermott, Raymond S.Bedke, JensTamada, SatoshiYin, LinaChen, MeiMolife, L. RhodaAtkins, Michael B.Powles, Thomas
- [43] First-line therapy for elderly patients with advanced renal cell carcinoma (aRCC): A systemic review and network meta-analysis.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Fujiwara, YuMiyashita, HirotakaLiaw, Bobby Chi-Hung
- [44] Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Motzer, Robert J.Porta, CamilloEto, MasatoshiPowles, ThomasGruenwald, ViktorHutson, Thomas E.Alekseev, BorisRha, Sun YoungMerchan, Jaime R.Goh, Jeffrey C.Kapoor, AnilDe Giorgi, UgoMelichar, BohuslavHong, Sung-HooGurney, HowardRodriguez-Lopez, KarlaHe, Cixin S.Okpara, ChinyereMcKenzie, JodiChoueiri, Toni K.
- [45] First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysisCLINICAL LUNG CANCER, 2019, 20 (05) : 331 - +Kim, RyulKeam, BhumsukHahn, SeokyungOck, Chan-YoungKim, MisoKim, Tae MinKim, Dong-WanHeo, Dae Seog
- [46] CLINICAL EFFICACY OF LENVATINIB PLUS EVEROLIMUS IN THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA: A FRACTIONAL POLYNOMIAL NETWORK META-ANALYSISVALUE IN HEALTH, 2019, 22 : S61 - S61McElroy, H. J.Schneider, K. B. A.Proudfoot, E. M.Pan, J. J.
- [47] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Wang, YufeiZhong, YichenMt-Isa, ShahrulPerini, RodolfoAdejoro, Oluwakayode
- [48] CABOZANTINIB VERSUS STANDARD OF CARE IN THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA: A NETWORK META-ANALYSISVALUE IN HEALTH, 2018, 21 : S16 - S16Lister, J.Schmidt, E.Marteau, F.Vataire, A.
- [49] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VERSUS PEMBROLIZUMAB PLUS AXITINIB (PEM plus AXI) FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- AND POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA PATIENTS IN COLOMBIAVALUE IN HEALTH, 2023, 26 (06) : S74 - S74Dhanji, N.Van, De Wetering G.Guiot, VBarco, VMejia, A.May, J. R.Garcia, J.Dyer, M.
- [50] Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N plus C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Shah, Amishi YogeshMotzer, Robert J.Apolo, Andrea B.Powles, ThomasEscudier, BernardZhang, JoshuaScheffold, ChristianKarumanchi, SravanLinh Thuy NguyenChoueiri, Toni K.